Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Santhera Pharmaceuticals
Switzerland’s Santhera is to restructure its business and seek extra funding after the failure of Puldysa (idebenone) in a Phase III Duchenne muscular dystrophy study at interim analysis.
Bausch seeks to add eyecare assets in Allegro deal. AstraZeneca hopes preclinical PCSK9 inhibitor from Dogma can compete with dyslipidemia leaders. Exelixis options ADC candidates from Catalent and NBE.
Deal Snapshot: Santhera acquires all rights to vamorolone from Idorsia, making it ReveraGen’s direct partner on the novel Duchenne muscular dystrophy therapy.
There is speculation that it is the end of the road for abicipar pegol but Allergan has declined to say whether this is the case for the product that has been in development for wet AMD.
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Oy Juvantia Pharma Ltd